Chester County News and Community Website
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE), a clinical-stage biopharmaceutical company, shared its financial results for 2024 and provided a progress update on its lead programs aimed at advancing cancer …
Aprea Therapeutics Reports 2024 Financial Results and Updates on Clinical Innovations Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has shared its corporate updates and financial results for the fourth quarter and full year of 2024, highlighting significant advancements in its clinical …
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position Read More
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has reported its financial results for the year ending December 31, 2024, while highlighting advancements in its clinical pipeline.
Context Therapeutics Reports 2024 Results and Outlines Clinical Advancements Read More
MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA) has reported its financial results for the fourth quarter and full year 2024. The company showcased a year of steady growth and operational …
TELA Bio Announces 2024 Financial Results and Positive 2025 Outlook Read More
PHILADELPHIA, PA — Five Below, Inc. (NASDAQ: FIVE) reported its financial results for the fourth quarter and full year of fiscal 2024, showcasing steady growth despite a challenging retail environment. The …
Five Below Reports Fiscal 2024 Results and Outlines Growth Plans for 2025 Read More
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) outlined a strategic pipeline re-prioritization and shared its financial results for the year 2024. This move aims to focus on potentially groundbreaking programs …
Century Therapeutics Announces Strategic Pipeline Shift and 2024 Financial Results Read More
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) released its financial results and operational highlights for 2024, marking significant strides in its pipeline and the broader development of DNA medicines.
INOVIO Reports Progress on INO-3107 and DNA Medicine, 2024 Financial Outcomes Read More
WILMINGTON, DE — Phreesia, Inc. (NYSE: PHR) has reported robust financial results for the fiscal fourth quarter and full year ended January 31, 2025, underscoring its continued growth and operational improvements. …
Phreesia Reports Strong Fiscal 2025 Results, Maintains Growth Outlook for 2026 Read More
WILMINGTON, DE — Global Indemnity Group, LLC (NYSE:GBLI) closed out 2024 with remarkable financial results, posting a 71% rise in net income available to shareholders, reaching $42.8 million or $3.12 per …
Global Indemnity Reports Robust 2024 Financial Performance Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has reported its financial results for the fourth quarter and full year ending December 31, 2024, marking significant progress in its turnaround …
Verrica Pharmaceuticals Reports Q4 2024 Growth and Pipeline Progress Read More